Trial of Poor Performance Status Patients (ToPPS)

• Status: Completed
• Trial end date: 2015-05-01

Summary

The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.

• Phase: Phase 2

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborator: Genentech, Inc.
• Treatments: Bevacizumab; Carboplatin; Pemetrexed